Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Raised by Pioneer Investment Management Inc.

Pioneer Investment Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 147,194 shares of the biopharmaceutical company’s stock after buying an additional 59,938 shares during the period. Pioneer Investment Management Inc. owned 0.17% of Alnylam Pharmaceuticals worth $11,740,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the stock. PNC Financial Services Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock valued at $446,000 after buying an additional 36 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Alnylam Pharmaceuticals by 4.7% in the second quarter. Bank of Montreal Can now owns 9,974 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 446 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares during the last quarter. Swiss National Bank increased its stake in shares of Alnylam Pharmaceuticals by 0.6% in the first quarter. Swiss National Bank now owns 127,700 shares of the biopharmaceutical company’s stock valued at $6,545,000 after buying an additional 800 shares during the last quarter. Finally, Aperio Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 9.8% in the second quarter. Aperio Group LLC now owns 16,085 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 1,432 shares during the last quarter. Hedge funds and other institutional investors own 88.96% of the company’s stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 78.22 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $86.92. The firm has a 50 day moving average of $80.94 and a 200-day moving average of $61.92. The stock’s market capitalization is $6.89 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same period in the prior year, the company posted ($1.05) EPS. The company’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post ($5.23) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Raised by Pioneer Investment Management Inc.” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/alnylam-pharmaceuticals-inc-nasdaqalny-position-raised-by-pioneer-investment-management-inc.html.

Several brokerages have recently commented on ALNY. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. Chardan Capital restated a “buy” rating and set a $124.00 price objective (down from $131.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Stifel Nicolaus restated a “buy” rating and set a $56.00 price objective (up from $47.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday. Ladenburg Thalmann Financial Services set a $80.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. Finally, Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price objective on the stock. in a research report on Monday, May 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $81.74.

In related news, VP Michael Mason sold 9,375 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the sale, the vice president now owns 5,625 shares of the company’s stock, valued at $393,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sanofi acquired 297,501 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The stock was purchased at an average cost of $71.87 per share, with a total value of $21,381,396.87. The disclosure for this purchase can be found here. Insiders sold 64,125 shares of company stock valued at $4,325,000 in the last three months. 4.30% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply